Update highlights effects of NOX-A12 monotherapy on tumor microenvironment in all recruited patients with evaluable tumor samples

The effectiveness of new drugs depends crucially on a fundamental understanding of the complex processes within the cells of the body. Scientists from Stanford University in California and the Charité – Universitätsmedizin Berlin have deciphered an…

Merus Initiates a Phase 1 Clinical Trial of MCLA-158, a Bispecific Antibody Utilizing ADCC-enhancing GlymaxX® Technology

New microscopy software enables precise monitoring of cells

The challenge is to develop a scalable, reliable, and cost-effective early-warning system prototype to forecast and monitor vector-borne diseases in order to contribute to the prevention of outbreaks, mitigating their impact on local, regional and…

At the World Health Summit, around 2,000 stakeholders and decision-makers from 100 countries and every field in the healthcare spectrum will work together to find solutions for global health challenges. As the world’s foremost strategic forum for…

Update highlights patient recruitment and effects of NOX-A12 monotherapy on the tumor microenvironment of a pancreatic tumor

Enhancers are regulatory regions of the DNA, giving rise to “long non-coding RNAs” (lncRNAs), which are known as crucial regulators of gene expression. Scientists from the Max Planck Institute for Molecular Genetics in Berlin now have shown that a…

ProBioGen AG, a premier service & technology provider for complex therapeutic glycoproteins, today announced that it has signed a second clinical immuno-oncology development and manufacturing agreement with Tizona Therapeutics, Inc., a privately held…